July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
TRAF3 (TNF Receptor-Associated Factor 3), a Potential Regulator of Retinal Inflammation, is Highly Expressed in the Murine Retina
Author Affiliations & Notes
  • Jami Gurley
    Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
  • Daniel J Carr
    Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
    Microbiology & Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
  • Michael H Elliott
    Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
  • Footnotes
    Commercial Relationships   Jami Gurley, None; Daniel Carr, None; Michael Elliott, None
  • Footnotes
    Support  R01EY019494, T32EY023202, P30EY021725, and Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4599. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jami Gurley, Daniel J Carr, Michael H Elliott; TRAF3 (TNF Receptor-Associated Factor 3), a Potential Regulator of Retinal Inflammation, is Highly Expressed in the Murine Retina. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4599.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Uncontrolled ocular inflammation leads to retinal tissue dysfunction and vision loss. We have recently identified Traf3 as a potential endogenous regulator of retinal inflammation following neuroretinal-Caveolin-1 depletion. The purpose of this study was 1) to develop a neuroretinal-specific Traf3 knockout (NR-Traf3 KO) mouse model, 2) to assess the efficiency of NR-Traf3 KO on whole retina TRAF3 protein expression, 3) to evaluate the effects of NR-Traf3 KO on visual function in young adult mice, and 4) to examine whether NR-Traf3 might play a role in retinal inflammatory protection.

Methods : NR-Traf3 KO (Chx10-Cre+/-/Traf3flox/flox) mice were generated by breeding Chx10-Cre recombinase carriers with Traf3-floxed mice (provided by Gail Bishop, U. Iowa). Efficiency of Traf3 retinal deletion was determined via Western blotting of NR-Traf3 KO and their Cre-/- littermates. Visual acuity, retinal structure, and retinal function were measured by OKT (Opto-Kinetic Tracking), IHC-H&E (immunohistochemistry-haemotoxylin & eosin)/OCT (Optical Coherence Tomography), and ERG (ElectroRetinoGraphy), respectively. Retinal cytokines/chemokines were measured by ELISA. Data are represented as mean ± SEM and analyzed by Student’s t-test, or 1- or 2-way ANOVA.

Results : NR-Traf3 KO, which targets Müller glia and neuronal cells, resulted in an ~70% reduction in whole retinal TRAF3 protein expression. At 2-3 months of age, neuroretinal-Traf3 depletion had no significant effect on retinal structure, retinal function, or visual acuity (ERG, a-wave p=0.89, b-wave p=0.74, n=3-7; OKT p=0.82, n=5-12). However, our preliminary data suggest that neuroretinal-Traf3 knockout mice have elevated levels of pro-inflammatory cytokines , and IL-6 levels increased 10-fold from 55±22 to 552±103 pg/mL. Additionally, in wild type animals, TRAF3 was reduced ~50% following 24h intravitreal LPS injection.

Conclusions : Our results support the novel hypothesis that Traf3 functions in the retina to mediate basal inflammatory suppression to protect the retina from inflammation-mediated retinal tissue damage. Because chronic ocular inflammation promotes retinal degeneration and vision loss, future studies will assess whether NR-Traf3 KO results in increased susceptibility to retinal inflammation and damage with age, and/or in response to ocular inflammatory challenge.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×